ESC 2014

Tous les comptes rendus

Études d'intervention

02 sep 2014

COPPS-2 : pas d’utilité de la colchicine avant la chirurgie cardiaque

M. Imazio (Italie) – COLchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial) – Hot Line : Cardiovascular disease : novel therapies

Diagnostic

02 sep 2014

Les causes de l’HTA secondaires résistantes

X. Jeunemaitre (France) – Secondary causes of resistant hypertension. Resistant hypertension in 2014.

Études d'intervention

02 sep 2014

Les modulateurs de la phospholipase A2 en difficulté

M. O’Donoghue (États-Unis) – The Stabilization Of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial : primary results – Hot Line : Coronary artery disease and lipids.

Études d'intervention

02 sep 2014

PARADIGM-HF : le changement, c’est maintenant !

M. Packer (États-Unis) – Results of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) – Hot Line : Cardiovascular disease : novel therapies.

Études d'intervention

02 sep 2014

Stimulation vagale dans l’insuffisance cardiaque : l’heure du doute

F. Zannad et coll. (France) – A randomized controlled trial of vagal stimulation for the treatment of systolic heart failure : Neural Cardiac TherApy foR Heart Failure (NECTAR-HF) – Hot Line : Cardiovascular disease : novel therapies.

Études d'intervention

02 sep 2014

POPE-2 : pas de réduction du risque d’effusion péricardique postchirurgie sous colchicine

P. Meurin (France) – Colchicine for post-operative pericardial effusion : The Post-Operative Pericardial Effusion (POPE-2) Study. A multicenter, double-blind, randomized trial. Hot Line : Cardiovascular disease : novel therapies.